To ask the Scottish Executive when the Health Technology Board for Scotland will issue guidance, in the light of current evidence, on the use of Beta Interferon A, Beta Interferon B and Copaxone in the treatment of primary progressive, secondary progressive and relapsing remitting multiple sclerosis.